Fazirsiran sodium is an antisense rnai oligonucleotide commercialized by Arrowhead Pharmaceuticals, with a leading Phase III program in Alpha-1 Antitrypsin Deficiency (A1AD). According to Globaldata, it is involved in 4 clinical trials, of which 2 were completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Fazirsiran sodium’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Fazirsiran sodium is expected to reach an annual total of $110 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Fazirsiran sodium Overview

ARO-AAT is under development for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD). The drug candidate is administered through subcutaneous route. It is a N-acetylgalactosamine-conjugated synthetic double-stranded oligomer specific to serpin family A member 1 gene. It is a follow-on product candidate of ARC-AAT targeting the mutant alpha-1antitrypsin (Z-AAT) protein and is developed based on RNAi platform technology.

Arrowhead Pharmaceuticals Overview

Arrowhead Pharmaceuticals (Arrowhead), formerly Arrowhead Research, is a pharmaceutical company. It develops and markets medicinal products including ARO-AAT, JNJ-3989, ARO-APOC3, ARO-ANG3, ARO-ENaC, ARO-HIF2, ARO-Lung2, ARO-HSD, ARO-HIF2, AMG 890, ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3.The company develops pipeline drugs that are being developed to treat chronic hepatitis B infection for the treatment of liver disease, cardiovascular disease, hypertriglyceridemia, dyslipidemia, cystic fibrosis and and renal cell carcinoma. It also offers design of internal preclinical and clinical development programs to enable novel new therapies. The company has operations in California and Wisconsin, the US. Arrowhead is headquartered in Pasadena, California, the US.

The company reported revenues of (US Dollars) US$243.2 million for the fiscal year ended September 2022 (FY2022), an increase of 75.9% over FY2021. The operating loss of the company was US$178.5 million in FY2022, compared to an operating loss of US$149 million in FY2021. The net loss of the company was US$176.1 million in FY2022, compared to a net loss of US$140.9 million in FY2021. The company reported revenues of US$62.6 million for the first quarter ended December 2022, an increase of 98.1% over the previous quarter.

For a complete picture of Fazirsiran sodium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.